UroGen Pharma Ltd (URGN): Next-Year EPS Estimate 235.86%
As of 2026-06-04, UroGen Pharma Ltd (URGN) has a next-year EPS growth estimate of 235.86%.
On 2026-05-31, analyst consensus for URGN's next-year EPS growth shifted from 262.32% to 235.86% — a negative change of 26.46 percentage points. The revised estimate has been sustained across 5 subsequent trading sessions. Current-year growth is projected at 71.64%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 235.86%
- EPS growth this year
- 71.64%
- EPS next quarter (est)
- -$0.30
- Last price
- $27.60
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 235.86% | 71.64% | -$0.30 | $27.60 |
| 2026-06-03 | 235.86% | 71.64% | -$0.30 | $26.60 |
| 2026-06-02 | 235.86% | 71.64% | -$0.30 | $26.54 |
| 2026-06-01 | 235.86% | 71.64% | -$0.30 | $27.03 |
| 2026-05-31 | 235.86% | 71.64% | -$0.30 | $28.13 |
| 2026-05-28 | 262.32% | 72.25% | -$0.29 | $28.69 |
| 2026-05-27 | 262.32% | 72.25% | -$0.29 | $29.33 |
| 2026-05-26 | 262.32% | 72.25% | -$0.29 | $29.46 |
| 2026-05-25 | 262.32% | 72.25% | -$0.29 | $28.89 |
| 2026-05-24 | 262.32% | 72.25% | -$0.29 | $28.89 |
| 2026-05-21 | 262.32% | 72.25% | -$0.29 | $29.88 |
| 2026-05-20 | 262.32% | 72.25% | -$0.29 | $30.22 |
| 2026-05-19 | 262.32% | 72.25% | -$0.29 | $28.26 |
| 2026-05-18 | 262.32% | 72.25% | -$0.29 | $28.58 |
| 2026-05-17 | 262.32% | 72.25% | -$0.29 | $28.78 |
| 2026-05-14 | 262.32% | 72.25% | -$0.29 | $29.68 |
| 2026-05-13 | 262.32% | 72.25% | -$0.29 | $30.64 |
| 2026-05-12 | 262.32% | 72.25% | -$0.29 | $29.80 |
| 2026-05-11 | 262.45% | 72.27% | -$0.29 | $31.33 |
| 2026-05-10 | 246.38% | 70.26% | -$0.30 | $29.40 |
| 2026-05-07 | 246.38% | 70.26% | -$0.30 | $26.59 |
| 2026-05-06 | 221.38% | 68.10% | -$0.33 | $26.25 |
| 2026-05-05 | 207.76% | 65.93% | -$0.48 | $23.83 |
| 2026-05-04 | 207.76% | 65.93% | -$0.48 | $23.29 |
| 2026-05-03 | 207.76% | 65.93% | -$0.48 | $23.00 |
| 2026-04-30 | 207.76% | 65.93% | -$0.48 | $23.83 |
| 2026-04-29 | 207.76% | 65.93% | -$0.48 | $23.34 |
| 2026-04-28 | 207.76% | 65.93% | -$0.48 | $24.12 |
| 2026-04-27 | 207.76% | 65.93% | -$0.48 | $23.77 |
| 2026-04-26 | 207.76% | 65.93% | -$0.48 | $24.11 |
Recent News
- UroGen Pharma Ltd. Q1 2026 Earnings Call SummaryMoby
- UroGen Pharma to Present at Upcoming Investor ConferencesGlobeNewswire
- UroGen Pharma to Present at Upcoming Investor ConferencesGlobeNewswire
- UroGen Reports ZUSDURI Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and HighlightsGlobeNewswire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is UroGen Pharma Ltd's next-year EPS growth estimate?▾
As of 2026-06-04, UroGen Pharma Ltd (URGN) has a next-year EPS growth estimate of 235.86%, based on analyst consensus.
When was the latest EPS estimate revision for URGN?▾
The most recent revision occurred on 2026-05-31, when analysts adjusted the next-year EPS growth estimate from 262.32% to 235.86%.
What sector and industry does UroGen Pharma Ltd belong to?▾
UroGen Pharma Ltd operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. URGN appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. UroGen Pharma Ltd (URGN) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports